Tango Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDTango Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 12% provides fundamental context to the price action. Investors should exercise caution due to high volatility (110% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $24.27 | -3.26% | BELOW |
| 50 SMA | $20.36 | +15.35% | ABOVE |
| 100 SMA | $15.72 | +49.35% | ABOVE |
| 150 SMA | $13.34 | +75.95% | ABOVE |
| 200 SMA | $11.76 | +99.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TNGX in an uptrend right now?
TNGX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TNGX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TNGX overbought or oversold?
TNGX's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is TNGX outperforming the market?
TNGX has a Relative Strength (RS) Rating of 97 out of 99. Yes, TNGX is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is TNGX in its 52-week range?
TNGX is trading at $23.48, which is 83% of its 52-week high ($28.41) and 82% above its 52-week low ($1.03).
How volatile is TNGX?
TNGX has a Beta of 1.81 and 52-week volatility of 110%. It's more volatile than the S&P 500 - expect bigger swings.